Poll

POLL: Will you use biosimilars in your ophthalmic practice?

Author(s):

Sheryl Stevenson

Let us know if you will plan to use biosimilars in your daily practice. The poll will be open until October 10, 2022.

Will you use biosimilars in your ophthalmic practice?

Yes, I plan to use biosimilars in my practice
No, I do not plan to use biosimilars in my practice

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
Related Content
Vantage Biosciences doses first patient in phase 2 study of VX-01, oral therapy for non-proliferative diabetic retinopathy
April 11th 2025

Vantage Biosciences doses first patient in phase 2 study of VX-01, oral therapy for non-proliferative diabetic retinopathy

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

(Image credit: AdobeStock/©rh2010)
April 10th 2025

Presbyopia treatment success begins with patient-centered care

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

(Image credit: AdobeStock/suphamit)
April 9th 2025

Novel multistage model enhances OCT GA segmentation

EMA application filed by Bayer to expand aflibercept 8 mg indication to include retinal vein occlusion
April 9th 2025

EMA application filed by Bayer to expand aflibercept 8 mg indication to include retinal vein occlusion

© 2025 MJH Life Sciences

All rights reserved.